Alicia Grande - 08 Dec 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
VP, Treasurer and CFO
Signature
/s/ Alicia Grande
Issuer symbol
CPRX
Transactions as of
08 Dec 2023
Net transactions value
-$1,283,780
Form type
4
Filing time
12 Dec 2023, 17:00:41 UTC
Previous filing
30 Mar 2023
Next filing
29 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $45,200 +40,000 +79% $1.13* 90,557 08 Dec 2023 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $285,000 -20,000 -22% $14.25 70,557 08 Dec 2023 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Sale $286,000 -20,000 -28% $14.30 50,557 08 Dec 2023 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Options Exercise $67,800 +60,000 +119% $1.13* 110,557 11 Dec 2023 Direct
transaction CPRX Common Stock, par value $0.001 per share Sale $412,200 -30,000 -27% $13.74 80,557 11 Dec 2023 Direct F1, F2
transaction CPRX Common Stock, par value $0.001 per share Sale $413,580 -30,000 -37% $13.79 50,557 11 Dec 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -40,000 -3.1% $0.000000 1,255,834 08 Dec 2023 Common Stock 40,000 $1.13 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -60,000 -4.8% $0.000000 1,195,834 11 Dec 2023 Common Stock 60,000 $1.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Ms. Grande sold the shares on the open market, for personal reasons, and to fund the exercise price and tax withholding of the exercise of the stock option, and not as a a result of any disagreement with the Company.
F2 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.74 to $13.745 per share.
F3 Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $13.78 to $13.79 per share.
F4 Options vested in three annual tranches beginning on January 3, 2018.